A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 1,830
- 主要终点
- IOP in the Study Eye at Week 12
研究概览
简要总结
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with primary open-angle glaucoma or ocular hypertension
- •Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient IOP control and is now being switched to Lumigan® UD for medical reasons
排除标准
- 未提供
研究组 & 干预措施
Patients with POAG or OHT
Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
干预措施: Bimatoprost Ophthalmic Solution (Drug)
结局指标
主要结局
IOP in the Study Eye at Week 12
时间窗: Week 12
IOP is a measurement of the fluid pressure inside the study eye.
Intraocular Pressure (IOP) in the Study Eye at Baseline
时间窗: Baseline
IOP is a measurement of the fluid pressure inside the study eye.
次要结局
- Number of Patients Who Discontinue Treatment With Lumigan® UD Prior to 12 Weeks of Treatment(12 Weeks)
- Physician Assessment of Tolerability on a 4-Point Scale(12 Weeks)
- Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale(Baseline, 12 Weeks)
- Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale(12 Weeks)
- Patient Assessment of Tolerability on a 4-Point Scale(12 Weeks)
- Number of Patients Who Continue Treatment(12 Weeks)